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Monocyte chemoattractant proteins in the pathogenesis of
systemic sclerosis
J. H. W. Distler1, A. Akhmetshina1, G. Schett1 and O. Distler2
Activation of the immune system and increased synthesis of extracellular matrix proteins by fibroblasts are hallmarks in the pathogenesis of
SSc. The molecular mechanisms underlying the infiltration of inflammatory cells into the skin and the subsequent activation of fibroblasts are
still largely unknown. Chemokines are a family of small molecules that are classified according to the position of the NH2-terminal cysteine
motif. Recent data indicate that chemokines and in particular two members of the subfamily of monocyte chemoattractant proteins, MCP-1
(CCL-2) and MCP-3 (CCL-7), might be involved in the pathogenesis of SSc. MCP-1 and -3 are overexpressed by SSc fibroblasts and in skin
lesions from SSc patients compared to healthy controls. MCP-1 and -3 are chemotactic for inflammatory cells and stimulate their migration
into the skin. In addition to their pro-inflammatory effects, MCP-1 and -3 contribute to tissue fibrosis by activating the synthesis of extracellular
matrix proteins in SSc fibroblasts. Therapeutic strategies targeting MCP-1 have revealed promising results in several animal models of SSc.
Antagonists against the receptor CCR2 are currently tested in clinical trials of a variety of diseases and also represent interesting candidates
for target-directed therapy in SSc.
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Introduction
SSc is a generalized fibrotic disease of unknown aetiology, which
affects the skin and various internal organs. Histopathological
hallmarks of SSc are inflammatory infiltrates in early disease
stages and an accumulation of extracellular matrix proteins
leading to tissue fibrosis. Inflammatory infiltrates are dominated
by macrophages and T cells, and are localized preferentially in
perivascular areas. Inflammatory cells migrate into the skin before
a significant accumulation of extracellular matrix can be observed.
Tissue fibrosis in SSc is caused by an overproduction of extra-
cellular matrix components by activated fibroblasts [1]. SSc
fibroblasts produce increased amounts of extracellular matrix
proteins that accumulate in the skin [2]. Although significant
progress has been made in analysing the different components
of the extracellular matrix, the mechanisms for the pathological
activation of fibroblasts in SSc have only partially been identi-
fied. Most authors favour an interaction of different cell types
orchestrated by pro-inflammatory and pro-fibrotic cytokines.
This concept is supported by the observation that fibroblasts,
which produce the highest amount of extracellular matrix
proteins, are often localized in close proximity to the inflamma-
tory infiltrates [1]. According to this hypothesis, pro-inflammatory
cytokines such as MCP-1 are released in early disease stages
of SSc. The pro-inflammatory cytokines attract T cells and
mononuclear cells to the skin, which in turn release pro-fibrotic
cytokines such as TGF- and IL-4 [1]. These pro-fibrotic
cytokines then activate in turn the synthesis of extracellular
matrix in dermal fibroblasts leading to tissue fibrosis in later
stages of the disease. However, the mechanisms that stimulate the
initial release of pro-inflammatory cytokines, which then trigger
the migration and activation of inflammatory cells in the early
pathogenesis of SSc, remain elusive.
Structure and classification of chemokines
Chemokines are a family of small molecules with a molecular
weight of 8–14 kDa. To date, 50 human chemokines and 20
G-protein-coupled chemokine receptors have been identified (see
supplementary tables 1–3, available as supplementary data at
Rheumatology Online). Based on their genetic organization and
the position of two highly conserved cysteine residues at the
N-terminus, chemokines can be divided into four subgroups,
the CC, CXC, C and CX3C families [3]. In the CXC chemokine
family, the two N-terminal cysteine residues are separated by a
variable amino acid. Genes from this family are clustered at
human chromosome 14q12-21. Based on the presence or absence
of a glutamic acid–leucine–arginine motif at the N-terminus, CXC
chemokines can be subclassified into ELRþ and ELRmolecules.
Chemokines of the CC family have adjacent cysteines close to the
N-terminus, and their genes cluster—with some exceptions—at
17q11.2-12 [4]. As a general rule, members of the CC family are
primarily targeting monocytes and T cells, whereas CXC
chemokines affect mainly neutrophils. The two members of the
C chemokine family, lymphotactin- and lymphotactin-, are
characterized by a single cysteine residue at the N-terminus. The
only member of the CX3C chemokine family, fractalkine, has
a typical chemokine domain at its N-terminus except for the
presence of three amino acids between the first two cysteines.
Fractalkine is the only chemokine that is membrane-bound [5].
Besides the chemokine domain, fractalkine also consists of a
mucin-like stalk, a transmembrane domain, which anchors it to
the plasma membrane, and a cytoplasmic domain. An alternative
classification system distinguishes inducible chemokines with pro-
inflammatory properties from homeostatic cytokines, which are
constitutively expressed [6].
Chemokine receptors
Chemokine receptors are seven-transmembrane-domain receptors,
which are coupled to heterotrimeric G-proteins [7]. To induce
migration of target cells along a chemotactic gradient, the release
of the  subunits from the heterotrimeric G-protein is required.
Among other pathways, the  subunits then directly activate
phosphoinositide-specific phospholipase C (PLC) isoenzymes
leading to the formation of inositol-1,4,5-trisphosphate and
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a rise of the intracellular calcium concentration. The signals
mediated by chemokine receptors (except CXCR 4) are short and
transient. The rapid termination of receptor activity is achieved by
phosphorylation at multiple sites of the cytoplasmic C-terminus,
homologous and heterologous desensitization and subsequent
internalization [7]. It is noteworthy that the chemokine/chemokine
receptor system is highly redundant, in that most chemokine
receptors bind several different chemokines and most chemokines
bind to several different receptors (see supplementary tables 1–3,
available as supplementary data at Rheumatology Online).
Function of chemokines
During inflammation, sentinel cells at the inflammatory focus
release chemokines and generate a chemotactic gradient to
surrounding blood vessels. Presentation of chemokines on endo-
thelial cells induces rolling and transendothelial migration of
leucocytes. For the migration along the chemotactic gradient,
sensing of subtle differences in the concentration of chemokines
is required. This occurs via the accumulation of intracellular
signalling molecules at the leading edge of migrating cells,
whereas the chemokine receptors themselves remain uniformly
distributed over the plasma membrane during migration [3, 8].
The mechanism whereby the chemotactic gradient leads to the
asymmetric distribution of intracellular signalling molecules
remains to be elucidated.
Although leucocyte chemotaxis and lymphocyte development
are the most prominent features of chemokines, chemokines also
possess other biological activities [3]. Of particular interest for
SSc, chemokines are also involved in the regulation of angio-
genesis and vasculogenesis. A structural domain of the CXC
chemokine family determines their angiogenic potential [9, 10].
The N-terminus of CXC family members such as IL-8 (CXCL8)
and growth-related oncogenes (GROs) ,  and  (CXCL1-3),
contain three amino acid residues (Glu–Leu–Arg), the so-called
ELR motif. These ELRþ CXC chemokines have strong chemo-
tactic effects on endothelial cells and can induce neovasculariza-
tion in vivo, even in the absence of leucocytes. In contrast,
ELR CXC chemokines, such as platelet factor 4 (CXCL4) and
monokine induced by IFN- (MIG, CXCL9), are potent
inhibitors of angiogenesis. Other functions of chemokines include
control of cell proliferation, alteration of the expression of
adhesion molecules and regulation of interactions between HIV
and target cells [10].
Expression of MCP-1 in the skin of SSc patients
Five members of the family of monocyte chemoattractant proteins
have been identified so far. MCP-1 (CCL2), MCP-2 (CCL8),
MCP-3 (CCL7), MCP-4 (CCL13) and MCP-5 (CCL12) constitute
a subfamily within the CC chemokines [11, 12]. The amino acid
sequences among the monocyte chemoattractant proteins are
highly conserved with up to 70% homology. They belong to the
functional class of inducible, pro-inflammatory chemokines and
have been shown to be chemotactic for monocytes, eosinophils
and basophils [11]. Two members of the family of monocyte
chemoattractant proteins, MCP-1 and -3, have been linked to the
pathogenesis of SSc.
MCP-1 (CCL2) is a 99-amino acid protein that has been shown
to be identical to the murine JE gene product [13]. MCP-1 can be
released by a large variety of cells including fibroblasts, epithelial
cells, mononuclear cells, endothelial cells and smooth muscle cells
[14–16]. In SSc, numerous groups have shown that MCP-1 is
expressed abundantly in the skin of patients on the mRNA and
protein level [17–20]. In skin biopsies from involved skin areas,
MCP-1 expression was detected by in situ hybridization and
immunohistochemistry in mononuclear cells, fibroblasts, endothe-
lial cells and keratinocytes. Interestingly, a similar expression
pattern for MCP-1 was also found at non-fibrotic skin sites,
suggesting that MCP-1 might play a role in the initiation of tissue
fibrosis [17]. In early, inflammatory stages, MCP-1 was expressed
mainly by infiltrating mononuclear cells, whereas in later, fibrotic
disease stages, fibroblasts became the major source for MCP-1 in
the dermis of SSc patients. In contrast, the expression of MCP-1
mRNA in the skin of healthy individuals was limited to a
few scattered epidermal and dermal cells and no expression of
MCP-1 protein was detectable on the protein levels by
immunohistochemistry.
In contrast to the situation in vivo, a constitutive expression of
MCP-1 mRNA and protein was detected in cultured fibroblasts
not only from SSc fibroblasts, but also from healthy controls [17].
The expression of MCP-1 was not only found in the presence of
fetal calf serum, but also after growth factor deprivation. The levels
of platelet-derived growth factor (PDGF) are elevated in SSc
patients and are thought to contribute to the pathogenesis of SSc.
We could demonstrate that PDGF induces dose-dependently the
expression of MCP-1 in cultured dermal fibroblasts. Concentra-
tions up to 10 ng/ml PDGF significantly induced MCP-1 mRNA
compared with unstimulated fibroblast cultures. In contrast to the
data obtained for MCP-1 protein, no further increase of MCP-1
mRNA was observed with higher concentrations of PDGF. These
data indicate that at higher concentrations of PDGF, the induction
of MCP-1 might be driven by increased translation, in addition to
increased transcription [17].
Karrer et al. [21] analysed in a limited number of German
SSc patients the frequency of the  2518G single nucleotide
polymorphism of the MCP-1 gene. They found that the GG
genotype was more frequent in their collection of SSc patients
than in healthy volunteers. Of particular interest, the expression of
MCP-1 was higher in GG homozygous patients than in patients
with the AG or the AA genotype. However, no significant
differences in the prevalence of this polymorphism were found in
two larger follow-up studies from the United Kingdom and from
the Czech Republic [22, 23].
MCP-1 in fibrotic diseases
In addition to increased expression in the skin, MCP-1 levels are
also increased in the blood of SSc patients [19, 24–27]. Serum
levels of MCP-1 might be particularly high in patients with early
and diffuse disease [25, 26]. However, another report did not find
changes in the serum concentrations of MCP-1 over time [24].
High serum levels of MCP-1 might also identify SSc patients with
increased risk of major organ involvement. Three groups reported
independently that serum levels of MCP-1 were higher in patients
with pulmonary fibrosis [19, 25, 27]. In addition, correlations with
renal and cardiac involvement have been described [25, 27].
MCP-1 is expressed in SSc from very early stages on and it is a
potent chemoattractant for mononuclear cells [28]. Local expres-
sion of MCP-1 in the skin of SSc patients might establish a
chemotactic gradient guiding inflammatory cells into the skin of
SSc patients. Indeed, experiments with blocking antibodies against
MCP-1 revealed that cultured fibroblasts from SSc patients
promote migration of mononuclear leucocytes by the release of
biologically active MCP-1 [17, 29]. MCP-1 might therefore play a
key role in the infiltration of the skin by mononuclear cells and
the development of inflammatory infiltrates in early stages of SSc,
which might stimulate in turn the activation of resident fibroblasts.
Indeed, inhibition of MCP-1 exerts potent anti-fibrotic effects
in several inflammation-driven models of tissue fibrosis. In a
murine model of crescentic nephritis, a strong induction of MCP-1
was observed that was accompanied by an influx of inflammatory
cells and the development of fibrosis [30]. Blocking MCP-1 by
anti-MCP-1 antibodies resulted in a reduced tissue infiltration by
inflammatory cells and a decreased deposition of type I collagen in
the kidney [31]. MCP-1 has also been suggested to play a role
in experimental pulmonary fibrosis. In bleomycin-induced lung
fibrosis, MCP-1 is expressed in a time-dependent manner after
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exposure to bleomycin with highest levels of MCP-1 observed in
areas of active fibrosis [32]. MCP-1 also plays a key role in the
pathogenesis of bleomycin-induced dermal fibrosis, a common
model of SSc. Mice lacking MCP-1 are protected from bleomycin-
induced dermal fibrosis [33]. The number of inflammatory cells
and the accumulation of collagen in lesional skin of mice lacking
MCP-1 upon bleomycin challenge were strongly reduced com-
pared with wild-type mice. Furthermore, treatment with SKL-
2841, a small molecule antagonist of MCP-1 and MIP-1,
prevented bleomycin-induced dermal fibrosis [34].
The important role of MCP-1 in pulmonary fibrosis was
supported by studies on mice lacking CCR2, the receptor for
MCP-1. After intratracheal instillation of bleomycin or FITC, the
hydroxyproline content of the lungs was significantly reduced in
CCR2 knockout animals compared with wild-type mice and
CCR2 knockout mice were protected from fibrosis [35, 36].
Activation of CCR2 signalling by MCP-1 and -5 might also
play an important role for the migration of fibrocytes into affected
tissues in fibrotic diseases. Fibrocytes are bone marrow derived,
circulating fibroblast-like cells that can be identified by their
expression of the haematopoietic stem cell antigen CD34, the
common leucocyte antigen CD45 and type I collagen. In culture,
these cells can acquire a myofibroblast phenotype and produce
large amounts of collagen. Fibrocytes have been implicated in the
pathogenesis of fibrotic disease in particular in pulmonary fibrosis
[37]. Murine fibrocytes isolated from fibrotic lungs expressed
CCR2 and migrated towards the CCR2 ligands MCP-1 and -5
in vitro [38]. In mice lacking CCR2, fibrocyte recruitment was
reduced upon challenge with intrapulmonary FITC. Recruitment
of fibrocytes in CCR2 knockout mice was restored, when CCR2
knockout mice were transplanted with bone marrow from wild-
type mice [38]. These findings demonstrate an important role for
CCR2 for the recruitment of fibrocytes in mice. However, CCR2
signalling might be less important in humans. First, human
fibrocytes express lower levels of CCR2 than murine fibrocytes
[39]. Second, no human homologue of the CCR2 agonist MCP-5
has been identified so far and MCP-5 might only be relevant to
murine biology.
Direct effects of MCP-1 on fibroblasts
Whether MCP-1 is directly involved in the activation of dermal
fibroblasts leading to the accumulation of extracellular matrix
proteins in SSc is controversial. We did not observe any effects
of recombinant MCP-1 on the synthesis of type I collagen in our
fibroblast cultures as assessed by real-time PCR, radioimmuno-
assay for the N-terminal propeptide of type I collagen and direct
measurements of the collagen concentrations with the SirCol
collagen assay [17, 40]. In addition, blocking antibodies to MCP-1
did not reduce the basal collagen synthesis of cultured fibroblasts
from SSc patients and healthy controls [40]. Our observations were
confirmed byGalindo and coworkers [18], who also did not observe
stimulatory effects of MCP-1 on cultured dermal fibroblasts.
Consistently, the receptor for MCP-1, CCR2, was not detectable in
our fibroblasts by real-time PCR, in situ hybridization and FACS
[40]. In contrast, Yamamoto et al. [41] detected a significant
increase of 1(I) collagen mRNA after incubation of cultured
dermal fibroblasts with recombinant MCP-1 by northern blot
hybridization. A possible explanation for these distinct findings
might be different cell sources, since Yamamoto et al. used out-
growth cultures, whereas fibroblasts were obtained from biopsies
by enzymatic digestion in the other studies. Alternatively, fibro-
blasts might express CCR2 only during a short time-frame in the
course of the disease and then lose the expression of receptors for
MCP-1. Along this line, Carulli et al. [42] detected signals for CCR2
by flow cytometry only in a subset of fibroblast cultures established
from patients with early SSc. Consistently, expression of CCR2was
detected only in patients with early, diffuse disease by immuno-
histochemistry. Double labelling experiments demonstrated that
CCR2-positive fibroblasts expressed -smooth muscle actin,
suggesting that the expression of CCR2 might be restricted
to myofibroblasts [42]. Of interest, CCR2 positive fibroblasts also
overexpressed MCP-1, suggesting a possible autocrine activation
loop in myofibroblasts. Indeed, inhibition of MCP-1 or CCR2
attenuated the expression of -smooth muscle actin. Thus, MCP-1
might stimulate the differentiation of a subset of resting fibroblasts
into metabolically active myofibroblasts in an autocrine manner in
early stages of SSc.
In addition to potential effects on collagen production, MCP-1
might also alter matrix turnover by regulating the expression
of matrix-degrading enzymes and their inhibitors. Yamamoto
and coworkers [43] demonstrated that MCP-1 up-regulates the
expression of tissue inhibitor of MMP-1 (TIMP-1) in dermal
fibroblasts on the mRNA and on the protein level. Of note, the
expression of MMP-1 and -2 was also increased. The induction of
MMP-1 might partially be mediated by IL-1. MCP-1 stimulated
the expression of IL-1 in parallel to MMP-1 and pre-incubation
with IL-1 receptor antagonist reduced the stimulatory effects of
MCP-1 on MMP-1 [43].
Alternative receptors for MCP-1 in SSc
Since only a subset of fibroblasts might express CCR2 for a short
time period, the expression of alternative receptors for MCP-1 in
SSc patients was analysed. Besides CCR2, three other receptors
have been shown to bind MCP-1, namely D6, the Duffy antigen
receptor for chemokines (DARC) and US28. In contrast to
CCR2, all of these receptors are not specific for MCP-1, but bind
several other cytokines with similar affinity. D6 is a seven-
transmembrane-spanning receptor that is most closely related
to CCR4 and IL-8R [44]. DARC was first identified as the
Duffy antigen on red blood cells. However, DARC is not only
expressed by erythrocytes, but also by numerous other cell types
including fibroblasts. Furthermore, the expression of DARC is
not limited to Duffy antigen-positive individuals, but also DARC
can be found in individuals whose erythrocytes do not express the
Duffy antigen [45]. To date, no signalling has been observed upon
binding of ligands to these receptors and D6 and DARC have
been suggested to function as decoy receptors [45, 46]. Consistent
with this hypothesis, mice lacking D6 exhibit severe hyperin-
flammatory responses. In contrast to D6 and DARC, US28
protein is a functional chemokine receptor [47, 48]. US28 protein
is encoded by the open reading frame 28 of the CMV [47, 48] and
has been shown to accelerate inflammation in the presence of
MCP-1 [49]. D6 and US28 were not expressed in the skin of SSc
patients or controls. mRNA for DARC was detectable in SSc
fibroblasts in vitro and in vivo. However, the expression levels were
low and no differences were observed between SSc patients and
healthy individuals [40]. Together with the fact that no signalling
has been detected upon chemokine binding to DARC, these data
suggest that DARC does not contribute to the activation of pro-
fibrotic signalling cascades by MCP-1 in SSc fibroblasts. In
summary, we did not detect any functional receptor for MCP-1 on
fibroblasts and direct stimulation of fibroblasts with MCP-1 did
not induce the synthesis of collagen.
Indirect, T-cell-dependent induction of collagen by MCP-1
MCP-1 has consistently been shown to be overexpressed in SSc.
Furthermore, animal models of different fibrotic diseases impli-
cate a pro-fibrotic role of MCP-1, but direct stimulatory effects of
MCP-1 on the collagen production by SSc fibroblasts have been
observed only in a subset of fibroblast cultures. Thus, the pro-
fibrotic effects of MCP-1 may require interactions with other cell
types such as T cells. In skin specimens of patients with SSc,
Mavalia et al. [50] found a predominance of Th2 cells, and there is
increasing evidence that Th2 cytokines contribute to the deposi-
tion of collagen in fibrotic diseases such as SSc. Among the Th2
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cytokines, IL-4 is thought to play an important role in the
pathogenesis of SSc. The levels of IL-4 are increased in the serum
of SSc patients [51] and IL-4 is also overexpressed in the skin of
SSc patients [52]. Furthermore, IL-4 has been shown to stimulate
the synthesis of extracellular matrix proteins in dermal fibroblasts
directly and potently [40, 53]. The importance of IL-4 for the
development of fibrosis in vivo is emphasized by the observation
that treatment with neutralizing anti-IL-4 antibodies prevents the
deposition of collagen in the tight-skin-1 mouse model of SSc and
leads to normalization of the dermal collagen content [54].
Consistent with the theory of an indirect role of MCP-1
in fibrotic processes, we recently demonstrated that MCP-1 can
induce a Th2 differentiation in Th0 cells resulting in an increased
release of IL-4 (Fig. 1) [40]. When Th0 cells were stimulated for
7 days by IL-2 and anti-CD3/CD28, the level of IL-4 released
by these T cells was significantly higher in the presence of MCP-1.
The level of MCP-1 increased further when the cells were
re-stimulated with MCP-1 and anti-CD3/CD28 after a resting
period of 4 days. We could also show that glycosaminoglycans
function as a local reservoir for MCP-1 in the skin of SSc patients
[40]. Like other components of the extracellular matrix, glycosa-
minoglycans are greatly enriched in the skin of patients with
SSc compared with healthy controls. The positively charged
C-terminus of MCP-1 can bind to negatively charged glycosami-
noglycans via ionic interactions [55, 56]. We could demonstrate
that MCP-1, which is re-released from glycosaminoglycans in a
time-dependent manner, is capable of stimulating efficiently the
production of IL-4 in Th0 cells [40].
Thus, direct and indirect effects might contribute to the pro-
fibrotic effects of MCP-1 in SSc. MCP-1 might directly stimulate
the collagen production in a subset of patients in early stages of
the disease. In other patients or in other stages of the disease, the
pro-fibrotic effects of MCP-1 might preferentially indirectly be
stimulating the release of IL-4 from T cells.
MCP-3 in the pathogenesis of SSc
MCP-3 (CCL7) is an 11 kDa protein that is closely related to
MCP-1. The chemotactic potency of MCP-3 for monocytic cells is
similar to that of MCP-1. However, the chemotactic effects of
MCP-3 are broader than that of MCP-1. Since MCP-3 binds not
only to CCR2, but also with high affinities to CCR1 and CCR3
[11], MCP-3 is also chemotactic for dendritic cells and granulo-
cytes in addition to monocytes, NK cells and lymphocytes [11, 57].
The expression patterns of MCP-3 are similar to MCP-1, but
MCP-3 is released in lower levels by dermal fibroblasts than
MCP-1 [58].
Tight-skin mice-1 (Tsk-1) are widely used as animal models of
SSc. Ong and co-workers [59] recently demonstrated that MCP-3
mRNA and protein are highly up-regulated in cultured fibroblasts
of neonatal Tsk. Immunohistochemistry demonstrated an abun-
dant expression of MCP-3 in the dermis of Tsk-1 mice. In con-
trast, the expression of MCP-3 was limited to perifollicular cells in
control mice. In SSc patients, MCP-3 was expressed by mono-
nuclear cells, dermal fibroblasts and basal keratinocytes of all
patients. In healthy individuals, MCP-3 was detected only in basal
keratinocytes. The release of MCP-3 was stimulated by TGF- in
murine fibroblasts [59]. The induction of MCP-3 by TGF-
depended partially on p42/44 ERK activation, since inhibitors of
p42/44 ERK prevented the up-regulation. MCP-3 might also play
a role in the pathological activation of skin fibroblasts in SSc. In
reporter assays, the promoter of the murine pro 2 (I) collagen
gene is activated by MCP-3 [59]. It has not been determined yet,
whether MCP-3 can up-regulate the collagen synthesis indirectly
by inducing the release of pro-fibrotic mediators by T cells. It has
not been determined yet, whether MCP-3 might also stimulate
Th2 polarization of T cells. Although the importance of MCP-3
needs to be confirmed in animal models for tissue fibrosis, MCP-3
might play an important role in the accumulation of extracellular
matrix in SSc.
Implications for therapy
During the last years, blocking of chemokine signalling has gained
growing interest as a potential new therapeutic strategy. In
general, the action of chemokines can be blocked by chemokine-
specific neutralizing antibodies, chemokine receptor antagonists
or the inhibition of intracellular signalling pathways, which are
activated by binding of chemokines to their receptors [60]. The
proof of concept that antagonizing of chemokines is a valid
therapeutic approach has been shown in animal models for a
variety of diseases. For example, administration of an N-terminal-
truncated MCP-1 analogue that exerts antagonistic effects on
CCR2 prevents the onset of arthritis in the MRL-lpr mouse model
of RA [61]. Furthermore, BX 471, a potent and specific CCR1
antagonist, has been developed, which can be administered orally
[62]. A new class of small molecule CCR2 antagonists was recently
evaluated [63, 64]. These small molecule CCR2 antagonists are
potent inhibitors of monocyte responses to MCP-1, and they are
specific for CCR2 and have appropriate pharmacokinetics for oral
applications in vivo. The efficiency of these antagonists was
investigated in several inflammatory conditions in vivo. In a mouse
model for delayed type hypersensitivity, the rodent-active CCR2
antagonist INCB3344 suppressed the influx of macrophages and
other inflammatory cells. Similar results were obtained with the
related inhibitor INCB3268 in primates [64]. These inhibitors
also blocked dose-dependently the influx of macrophages into the
peritoneal cavity after thioglycolate challenge [63]. Furthermore,
treatment with INCB3344, has been shown to reduce the clinical
signs of adjuvant arthritis efficiently, when initiated at the onset of
arthritis. Histological analysis demonstrated not only a marked
suppression of inflammation, but also a significant reduction
of bone resorption [63]. The authors claimed that CCR2 antago-
nists might selectively inhibit the inflammatory phases, but not
affecting immune activation, and that CCR2 inhibitors might
therefore represent a novel class of anti-inflammatory drugs
without severe immunosuppressive side-effects. Because of the
FIG. 1. Proposed function of MCP-1 (CCL2) in the pathogenesis of systemic
sclerosis. Dermal fibroblasts act as sentinel cells and release MCP-1 in early
stages of SSc. PDGF and IL-1 contribute to the induction of MCP-1 in dermal
fibroblasts, resulting in a further increase of the expression of MCP-1. MCP-1
attracts mononuclear cells across the endothelial cell barrier into the dermis. MCP-
1 might stimulate directly the expression of collagen in a subset of SSc fibroblasts.
MCP-1 contributes also indirectly to the accumulation of extracellular matrix in
SSc. MCP-1 induces a Th2 differentiation in infiltrating Th0 cells. Th2 cells release
increased amounts of IL-4, which stimulates in turn the collagen synthesis in SSc
fibroblasts. In this model, glycosaminoglycans function as a local reservoir for
MCP-1. (Figure modified from [40]).
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encouraging animal data, this group of small molecule CCR2
inhibitors is currently evaluated in clinical trials [63].
Harringman and colleagues [65] chose a different approach
to target MCP-1 signalling. Instead of using a small molecule
inhibitor of CCR2, they used monoclonal human anti-MCP-1
antibodies (ABN912) and evaluated their efficacy for the
treatment of RA in a placebo-controlled dose escalation trial.
ABN912 was well tolerated with no differences in the incidence of
adverse events between placebo and treatment groups. However,
after an initial drop, the total serum levels of MCP-1 unexpectedly
increased dose-dependently up to 2000-fold in patients treated
with ABN912 and remained elevated throughout the observation
period of 180 days [65]. These effects might be explained by rapid
binding of intravascular MCP-1 by ABN912 and subsequent
mobilization of MCP-1 from extravascular compartments,
e.g. from glycosaminoglycans. Consistent with the increase in
circulating MCP-1, no clinical improvement was seen in patients
treated with ABN912. Instead, the serum levels of CRP and the
number of sublining macrophages tended to increase in patients
treated with ABN912. The results of this study do question
the strategy of targeting MCP-1 with neutralizing antibodies,
because subsequent increases in serum levels might be a general
phenomenon for MCP-1 and all other chemokines that bind to
glycosaminoglycans, and are therefore stored in large quantities in
the extracellular matrix. In general, strategies targeting CCR2
might be more potent than inhibition of MCP-1 for two reasons:
(i) inhibitors of CCR2 should not lead to a mobilization of MCP-1
from extravascular stores, (ii) CCR2 is also a receptor for MCP-3
and inhibition of CCR2 thus targets simultaneously two pro-
fibrotic cytokines, MCP-1 and -3. CCR2 antagonists are currently
developed by a number of different pharmaceutical companies
and are tested in clinical trials for various diseases. Table 1
summarizes the current status of clinical testing of these CCR2
antagonists. However, a recent trial with the human CCR2
blocking antibody MLN1202 in patients with RA failed to show
improvement [66]. Treatment with MLN1202 reduced the levels of
free CCR2 on synovial monocytes, but did not alter the expression
of synovial biomarkers or the clinical course. This controlled
Phase IIa trial was underpowered with only seven to nine patients
per group and was thus not designed to detect clinical outcome.
Furthermore, the observation time was limited to 6 weeks.
Prolonged treatment might be needed before beneficial effects
can be detected. Finally, the authors also focused on markers of
monocyte activation and did not analyse fibroblasts and T cells,
which are thought to mediate the pro-fibrotic effects of MCPs in
SSc. Thus, the results of this trial do not exclude inefficacy of
CCR2 antagonists in SSc.
Summary
MCP-1 and -3 have been characterized as important players in the
pathogenesis of SSc that might control inflammation of fibrosis.
MCP-1 is overexpressed in the skin of SSc patients and is able to
initiate the migration of inflammatory cells from the blood into
involved tissues. MCP-1 plays also an important role in the
development of skin fibrosis in SSc. MCP-1 induces a Th2
differentiation in Th0 cells. Th2 cells release increased amounts of
IL-4, which stimulates in turn the collagen synthesis in dermal
fibroblasts. In addition, MCP-1 might stimulate directly the
production of extracellular matrix proteins in a subset of SSc
fibroblasts. MCP-3 is overexpressed as well in SSc and activates
collagen production in dermal fibroblasts. Targeting of MCP-1
and -3 might offer a great potential for novel therapeutic agents.
Inhibitors of the MCP receptor CCR2 have been developed
recently and are currently tested in clinical trials.
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 Inhibition of MCP-1 signalling had promising anti-fibrotic effects in
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 Antagonists against the receptor CCR2 might represent interest-
ing candidates for target-directed therapy in SSc.
102 J. H. W. Distler et al.
11 Proost P, Wuyts A, Van Damme J. Human monocyte chemotactic proteins-2 and -3:
structural and functional comparison with MCP-1. J Leukoc Biol 1996;59:67–74.
12 Sheikine Y, Hansson GK. Chemokines and atherosclerosis. Ann Med 2004;
36:98–118.
13 Rollins BJ, Morrison ED, Stiles CD. Cloning and expression of JE, a gene inducible
by platelet-derived growth factor and whose product has cytokine-like properties.
Proc Natl Acad Sci USA 1988;85:3738–42.
14 Standiford TJ, Kunkel SL, Phan SH, Rollins BJ, Strieter RM. Alveolar macrophage-
derived cytokines induce monocyte chemoattractant protein-1 expression from
human pulmonary type ii-like epithelial cells. J Biol Chem 1991;266:9912–8.
15 Yla-Herttuala S, Lipton BA, Rosenfeld ME et al. Expression of monocyte
chemoattractant protein 1 in macrophage-rich areas of human and rabbit athero-
sclerotic lesions. Proc Natl Acad Sci USA 1991;88:5252–6.
16 Yoshimura T, Yuhki N, Moore SK, Appella E, Lerman MI, Leonard EJ. Human
monocyte chemoattractant protein-1 (MCP-1). Full-length cDNA cloning, expression
in mitogen-stimulated blood mononuclear leukocytes, and sequence similarity to
mouse competence gene JE. FEBS Lett 1989;244:487–93.
17 Distler O, Pap T, Kowal-Bielecka O et al. Overexpression of monocyte chemoat-
tractant protein 1 in systemic sclerosis: role of platelet-derived growth factor
and effects on monocyte chemotaxis and collagen synthesis. Arthritis Rheum
2001;44:2665–78.
18 Galindo M, Santiago B, Rivero M, Rullas J, Alcami J, Pablos JL. Chemokine
expression by systemic sclerosis fibroblasts: abnormal regulation of monocyte
chemoattractant protein 1 expression. Arthritis Rheum 2001;44:1382–6.
19 Hasegawa M, Sato S, Takehara K. Augmented production of chemokines (monocyte
chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1alpha
(MIP-1alpha) and MIP-1beta) in patients with systemic sclerosis: MCP-1 and
MIP-1alpha may be involved in the development of pulmonary fibrosis. Clin Exp
Immunol 1999;117:159–65.
20 Yamamoto T, Eckes B, Hartmann K, Krieg T. Expression of monocyte chemoat-
tractant protein-1 in the lesional skin of systemic sclerosis. J Dermatol Sci
2001;26:133–9.
21 Karrer S, Bosserhoff AK, Weiderer P et al. The -2518 promotor polymorphism in the
MCP-1 gene is associated with systemic sclerosis. J Invest Dermatol 2005;124:92–8.
22 Carulli MT, Spagnolo P, Fonseca C et al. Single-nucleotide polymorphisms in ccl2
gene are not associated with susceptibility to systemic sclerosis. J Rheumatol
2008;35:839–44.
23 Navratilova Z, Lukac J, Mrazek F et al. MCP-1 -2518 a/g single nucleotide
polymorphism in Slovak patients with systemic sclerosis. Mediators Inflamm
2008;2008:204063.
24 Antonelli A, Ferri C, Fallahi P et al. CXCl10 (alpha) and CCL2 (beta) chemokines in
systemic sclerosis—a longitudinal study. Rheumatology 2008;47:45–9.
25 Carulli MT, Handler C, Coghlan JG, Black CM, Denton CP. Can CCL2 serum levels
be used in risk stratification or to monitor treatment response in systemic sclerosis?
Ann Rheum Dis 2008;67:105–9.
26 Peterlana D, Puccetti A, Caramaschi P et al. Endothelin-1 serum levels correlate with
MCP-1 but not with homocysteine plasma concentration in patients with systemic
sclerosis. Scand J Rheumatol 2006;35:133–7.
27 Scala E, Pallotta S, Frezzolini A et al. Cytokine and chemokine levels in systemic
sclerosis: relationship with cutaneous and internal organ involvement. Clin Exp
Immunol 2004;138:540–6.
28 Yamamoto T. Pathogenic role of CCL2/MCP-1 in scleroderma. Front Biosci
2008;13:2686–95.
29 Denton CP, Shi-Wen X, Sutton A, Abraham DJ, Black CM, Pearson JD. Scleroderma
fibroblasts promote migration of mononuclear leucocytes across endothelial cell
monolayers. Clin Exp Immunol 1998;114:293–300.
30 Lloyd CM, Minto AW, Dorf ME et al. RANTES and monocyte chemoattractant
protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic
nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis.
J Exp Med 1997;185:1371–80.
31 Wada T, Yokoyama H, Furuichi K et al. Intervention of crescentic glomerulonephritis
by antibodies to monocyte chemotactic and activating factor (MCAF/MCP-1). FASEB
J 1996;10:1418–25.
32 Zhang K, Gharaee-Kermani M, Jones ML, Warren JS, Phan SH. Lung monocyte
chemoattractant protein-1 gene expression in bleomycin-induced pulmonary fibrosis.
J Immunol 1994;153:4733–41.
33 Ferreira AM, Takagawa S, Fresco R, Zhu X, Varga J, DiPietro LA. Diminished
induction of skin fibrosis in mice with MCP-1 deficiency. J Invest Dermatol
2006;126:1900–8.
34 Kimura M, Kawahito Y, Hamaguchi M et al. Skl-2841, a dual antagonist of MCP-1
and MIP-1 beta, prevents bleomycin-induced skin sclerosis in mice. Biomed
Pharmacother 2007;61:222–8.
35 Moore BB, Paine R 3rd, Christensen PJ et al. Protection from pulmonary fibrosis in
the absence of CCR2 signaling. J Immunol 2001;167:4368–77.
36 Okuma T, Terasaki Y, Kaikita K et al. C-C chemokine receptor 2 (CCR2) deficiency
improves bleomycin-induced pulmonary fibrosis by attenuation of both macrophage
infiltration and production of macrophage-derived matrix metalloproteinases. J Pathol
2004;204:594–604.
37 Strieter RM, Gomperts BN, Keane MP. The role of CXC chemokines in pulmonary
fibrosis. J Clin Invest 2007;117:549–56.
38 Moore BB, Kolodsick JE, Thannickal VJ et al. CCR2-mediated recruitment of
fibrocytes to the alveolar space after fibrotic injury. Am J Pathol 2005;166:675–84.
39 Hong KM, Burdick MD, Phillips RJ, Heber D, Strieter RM. Characterization of human
fibrocytes as circulating adipocyte progenitors and the formation of human adipose
tissue in scid mice. FASEB J 2005;19:2029–31.
40 Distler JH, Jungel A, Caretto D et al. Monocyte chemoattractant protein 1 released
from glycosaminoglycans mediates its profibrotic effects in systemic sclerosis via the
release of interleukin-4 from T cells. Arthritis Rheum 2006;54:214–25.
41 Yamamoto T, Eckes B, Krieg T. Effect of interleukin-10 on the gene expression of
type I collagen, fibronectin, and decorin in human skin fibroblasts: differential
regulation by transforming growth factor-beta and monocyte chemoattractant
protein-1. Biochem Biophys Res Commun 2001;281:200–5.
42 Carulli MT, Ong VH, Ponticos M et al. Chemokine receptor CCR2 expression by
systemic sclerosis fibroblasts: evidence for autocrine regulation of myofibroblast
differentiation. Arthritis Rheum 2005;52:3772–82.
43 Yamamoto T, Eckes B, Mauch C, Hartmann K, Krieg T. Monocyte chemoattractant
protein-1 enhances gene expression and synthesis of matrix metalloproteinase-1 in
human fibroblasts by an autocrine IL-1 alpha loop. J Immunol 2000;164:6174–9.
44 Nibbs RJ, Wylie SM, Pragnell IB, Graham GJ. Cloning and characterization of a
novel murine beta chemokine receptor, D6. Comparison to three other related
macrophage inflammatory protein-1alpha receptors, CCR-1, CCR-3, and CCR-5.
J Biol Chem 1997;272:12495–504.
45 Patterson AM, Siddall H, Chamberlain G, Gardner L, Middleton J. Expression of the
duffy antigen/receptor for chemokines (DARC) by the inflamed synovial endothelium.
J Pathol 2002;197:108–16.
46 Darbonne WC, Rice GC, Mohler MA et al. Red blood cells are a sink for interleukin 8,
a leukocyte chemotaxin. J Clin Invest 1991;88:1362–9.
47 Casarosa P, Bakker RA, Verzijl D et al. Constitutive signaling of the human
cytomegalovirus-encoded chemokine receptor US28. J Biol Chem 2001;276:1133–7.
48 Kuhn DE, Beall CJ, Kolattukudy PE. The cytomegalovirus US28 protein binds
multiple CC chemokines with high affinity. Biochem Biophys Res Commun
1995;211:325–30.
49 Froberg MK, Adams A, Seacotte N, Parker-Thornburg J, Kolattukudy P.
Cytomegalovirus infection accelerates inflammation in vascular tissue overexpres-
sing monocyte chemoattractant protein-1. Circ Res 2001;89:1224–30.
50 Mavalia C, Scaletti C, Romagnani P et al. Type 2 helper T-cell predominance and
high CD30 expression in systemic sclerosis. Am J Pathol 1997;151:1751–8.
51 Needleman BW, Wigley FM, Stair RW. Interleukin-1, interleukin-2, interleukin-4,
interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from
patients with scleroderma. Arthritis Rheum 1992;35:67–72.
52 Salmon-Ehr V, Serpier H, Nawrocki B et al. Expression of interleukin-4 in
scleroderma skin specimens and scleroderma fibroblast cultures. Potential role in
fibrosis. Arch Dermatol 1996;132:802–6.
53 Makhluf HA, Stepniakowska J, Hoffman S, Smith E, LeRoy EC, Trojanowska M. IL-4
upregulates tenascin synthesis in scleroderma and healthy skin fibroblasts. J Invest
Dermatol 1996;107:856–9.
54 Ong C, Wong C, Roberts CR, Teh HS, Jirik FR. Anti-IL-4 treatment prevents dermal
collagen deposition in the tight-skin mouse model of scleroderma. Eur J Immunol
1998;28:2619–29.
55 Chakravarty L, Rogers L, Quach T, Breckenridge S, Kolattukudy PE. Lysine 58 and
histidine 66 at the c-terminal alpha-helix of monocyte chemoattractant protein-1 are
essential for glycosaminoglycan binding. J Biol Chem 1998;273:29641–7.
56 Kuschert GS, Coulin F, Power CA et al. Glycosaminoglycans interact selectively with
chemokines and modulate receptor binding and cellular responses. Biochemistry
1999;38:12959–68.
57 Van Damme J, Proost P, Lenaerts JP, Opdenakker G. Structural and functional
identification of two human, tumor-derived monocyte chemotactic proteins (MCP-2
and MCP-3) belonging to the chemokine family. J Exp Med 1992;176:59–65.
58 Menten P, Proost P, Struyf S et al. Differential induction of monocyte chemotactic
protein-3 in mononuclear leukocytes and fibroblasts by interferon-alpha/beta and
interferon-gamma reveals MCP-3 heterogeneity. Eur J Immunol 1999;29:678–85.
59 Ong VH, Evans LA, Shiwen X et al. Monocyte chemoattractant protein 3 as a
mediator of fibrosis: overexpression in systemic sclerosis and the type 1 tight-skin
mouse. Arthritis Rheum 2003;48:1979–91.
60 Proudfoot AE, Power CA, Wells TN. The strategy of blocking the chemokine system
to combat disease. Immunol Rev 2000;177:246–56.
61 Gong JH, Ratkay LG, Waterfield JD, Clark-Lewis I. An antagonist of monocyte
chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-lpr mouse model.
J Exp Med 1997;186:131–7.
62 Liang M, Mallari C, Rosser M et al. Identification and characterization of a potent,
selective, and orally active antagonist of the CC chemokine receptor-1. J Biol Chem
2000;275:19000–8.
63 Brodmerkel C, Collins R, Hall L et al. Evaluation of a small molecule CCR2
antagonist in a rat model of rheumatoid arthritis. Arthritis Rheum 2004;50(Suppl. 9):
S369.
64 Brodmerkel C, Huber R, Collins R et al. CCR2 antagonism is a novel approach to
modulate cell-mediated immune responses without immunosuppression. Arthritis
Rheum 2004;58:587.
65 Haringman JJ, Gerlag DM, Smeets TJ et al. A randomized controlled trial with an
anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients
with rheumatoid arthritis. Arthritis Rheum 2006;54:2387–92.
66 Vergunst CE, Gerlag DM, Lopatinskaya L et al. Modulation of CCR2 in rheumatoid
arthritis: a double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum
2008;58:1931–9.
MCPs in SSc 103
